Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05556512 · ClinicalTrials.gov registry record · Phase 3
A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity
A Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
- Active
- Registry status
- Phase 3
- Development phase
- 15,374
- Enrollment target
- 20
- Study locations
NCT05556512: Active Phase 3 study of Obesity and Overweight, sponsored by Eli Lilly and Company.
NCT05556512 is a Phase 3 study of Obesity and Overweight that is active but no longer recruiting, run by Eli Lilly and Company. The registered enrollment target is 15,374 participants, above the 804-participant average among 1,053 other Obesity trials with a reported enrollment target (1812% higher). The trial reports 20 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05556512, a Phase 3 study of Obesity and Overweight, is active but no longer recruiting, sponsored by Eli Lilly and Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 15,374 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tirzepatide
Study Locations (20)
California
- Smart Cures Clinical Research - Anaheim
- Kidney & Hypertension Center - Apple Valley - Apple Valley
- Hope Clinical Research, Inc. - Canoga Park
- John Muir Physician Network Research Center - Concord
- Neighborhood Healthcare Institute of Health - Escondido
- HB Clinical Trials - Fountain Valley - Fountain Valley
- Valiance Clinical Research - Huntington Park
- Scripps Whittier Diabetes Institute - La Jolla
- Velocity Clinical Research, San Diego - La Mesa
- First Valley Medical Group - Lancaster
- Long Beach Clinical Trials - Long Beach
- Infinity Clinical Research - Norco - Norco
- California Medical Research Associates - Northridge
- Diabetes Associates Medical Group - Orange
- University of California Irvine Medical Center - Orange
Arizona
- Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC - Gilbert
- Aventiv Research - Mesa
- Elite Clinical Studies - Phoenix
- Pima Heart - Tucson
Arkansas
- KLR Business Group, Inc. dba Arkansas Clinical Research - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15,374 participants |
| Start Date | 2022-10-11 |
| Est. Completion | 2027-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05556512
The ClinicalTrials.gov registry entry for NCT05556512 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 15,374 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 804-participant average among 1,053 other Obesity trials with a reported enrollment target (1812% higher). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05556512 reports 20 study locations spanning 3 distinct geographic areas - top geographies include California, Arizona, Arkansas.
Frequently Asked Questions
What is clinical trial NCT05556512 about?
NCT05556512 is a clinical study titled "A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity". This study will investigate the effect of tirzepatide on the reduction of morbidity and mortality in adults living with obesity and provide additional evidence for the potential clinical benefits of tirzepatide in this population.
What is the current status of trial NCT05556512?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 15,374 participants. The study started on 2022-10-11. Estimated completion is 2027-10.
What conditions does trial NCT05556512 study?
This clinical trial studies the following conditions: Obesity, Overweight.
What interventions are being tested in trial NCT05556512?
The interventions under investigation include: Placebo (DRUG), Tirzepatide (DRUG).
Who is sponsoring clinical trial NCT05556512?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05556512 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.